Global Prevalence and Major Risk Factors of Diabetic Retinopathy
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To examine the global prevalence and major risk factors for diabetic retinopathy (DR) and vision-threatening diabetic retinopathy (VTDR) among people with diabetes. RESEARCH DESIGN AND METHODS: A pooled analysis using individual participant data from population-based studies around the world was performed. A systematic literature review was conducted to identify all population-based studies in general populations or individuals with diabetes who had ascertained DR from retinal photographs. Studies provided data for DR end points, including any DR, proliferative DR, diabetic macular edema, and VTDR, and also major systemic risk factors. Pooled prevalence estimates were directly age-standardized to the 2010 World Diabetes Population aged 20–79 years. RESULTS: A total of 35 studies (1980–2008) provided data from 22,896 individuals with diabetes. The overall prevalence was 34.6% (95% CI 34.5–34.8) for any DR, 6.96% (6.87–7.04) for proliferative DR, 6.81% (6.74–6.89) for diabetic macular edema, and 10.2% (10.1–10.3) for VTDR. All DR prevalence end points increased with diabetes duration, hemoglobin A1c, and blood pressure levels and were higher in people with type 1 compared with type 2 diabetes. CONCLUSIONS: There are approximately 93 million people with DR, 17 million with proliferative DR, 21 million with diabetic macular edema, and 28 million with VTDR worldwide. Longer diabetes duration and poorer glycemic and blood pressure control are strongly associated with DR. These data highlight the substantial worldwide public health burden of DR and the importance of modifiable risk factors in its occurrence. This study is limited by data pooled from studies at different time points, with different methodologies and population characteristics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The prognosis for retaining vision has improved dramatically over the past 40 years owing to improved metabolic and BP control.78,432,488–490”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [488]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Globally, the overall prevalence of referable DR has been estimated to be around 10%, but this varies across geographic regions, ethnicities, and study methodologies33.”
From Economic evaluation for medical artificial intelligence: accuracy vs. cost-effectiveness in a diabetic retinopathy screening case (2024) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients diagnosed with kidney disease, hypertension, and covered under Medicaid insurance are at higher risk for poor visual outcomes13–24.”
From Autonomous AI-assisted diabetic retinopathy screening at primary care is associated with increased presentation to eye care by at risk patients (2026) · cites this paper as [13]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Diabetic retinopathy (DR) is the leading cause of blindness among working-aged adults and early detection is critical for timely management to prevent vision loss1,2.”
From Referral uptake after diabetic retinopathy screening with artificial intelligence-assisted care pathways: a systematic review and meta-analysis (2026) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Artificial intelligence (AI) is an accurate screening tool for diabetic retinopathy (DR), the leading cause of blindness among working-aged adults.”
From Referral uptake after diabetic retinopathy screening with artificial intelligence-assisted care pathways: a systematic review and meta-analysis (2026) · cites this paper as [2]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Global estimates of the prevalence of diabetes for 2010 and 2030
Shaw, J. E., Sicree, R. A., & Zimmet, P. Z. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.007 · Cited by 7,216
Self-citationColhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755 · cited 1×
“Statins, however, did not affect DR severity in the few studies in which this was evaluated, although not as a primary outcome (35,36).”
Prevalence of Diabetes among Men and Women in China
Yang, W., Lu, J., Weng, J., Jia, W., Ji, L., Xiao, J., Shan, Z., Liu, J., Tian, H., Ji, Q., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908292 · Cited by 3,031
Klein, R. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040030398010 · Cited by 1,885 · cited 1×
“We showed that the prevalence of DR is substantially higher in type 1 than in type 2 diabetes (11,37), an outcome independent of diabetes duration.”
Self-citationKlein, R. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040030405011 · Cited by 1,477 · cited 1×
“If data on age at diagnosis of diabetes were available in these studies, participants were classified as type 1 if they were diagnosed before age 30 years and as type 2 if they were diagnosed with diabetes after age 30 years, as previously used in one study (7).”
Self-citationKlein, R., Klein, B. E. K., Moss, S. E., & Linton, K. L. P. (1992) · Ophthalmology · doi:10.1016/s0161-6420(92)32011-1 · Cited by 1,340
Self-citation
Cited by
Items 501–600 of 1,029
Assessing Progress in Retinopathy Outcomes in Type 1 Diabetes
LeCaire, T. J., Palta, M., Klein, R., Klein, B. E. K., & Cruickshanks, K. J. (2013) · Diabetes Care · doi:10.2337/dc12-0863 · Cited by 67
Self-citationKeenan, T. D. L., Johnston, R. L., Donachie, P. H. J., Sparrow, J. M., STRATTON, I. M., & Scanlon, P. H. (2013) · Eye · doi:10.1038/eye.2013.196 · Cited by 69
Beyond Lesion-Based Diabetic Retinopathy: A Direct Approach for Referral
Pires, R., Avila, S., Jelinek, H. F., Wainer, J., Junior, E. A. D. V., & Rocha, A. D. R. (2015) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2015.2498104 · Cited by 74
Iglicki, M., Lavaque, A. J., Ozimek, M. A., Negri, H. P., Okada, M., Chhablani, J. K., Busch, C., Loewenstein, A., & Zur, D. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200365 · Cited by 69
Singh, N., Kaur, L., & Singh, K. (2019) · Engineering Science and Technology an International Journal · doi:10.1016/j.jestch.2019.01.014 · Cited by 87
Bursell, S.-E., Fonda, S. J., Lewis, D. G., & Horton, M. B. (2018) · PLOS ONE · doi:10.1371/journal.pone.0198551 · Cited by 68
High HDL cholesterol: A risk factor for diabetic retinopathy? Findings from NO BLIND study
Sasso, F. C., Pafundi, P. C., Gelso, A., Bono, V., Costagliola, C., Marfella, R., Sardu, C., Rinaldi, L., Galiero, R., Acierno, C., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.03.028 · Cited by 70
Ghareghomi, S., Rahban, M., Moosavi‐Movahedi, Z., Habibi-Rezaei, M., Saso, L., & Moosavi‐Movahedi, A. A. (2021) · Molecules · doi:10.3390/molecules26247658 · Cited by 76
Long-term Outcomes in Youths with Diabetes Mellitus
White, N. H. (2015) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2015.04.004 · Cited by 79
“Other factors that were reported to be associated include microalbuminuria (28,37,44), puberty (31,39), blood pressure (44,45), female (29) or male (36) gender, BMI (44) and LDL cholesterol (43); however, these associations were not explored in all studies and not consistently associated when they were explored.”
Mehta, H., Hennings, C., Gillies, M. C., Nguyen, V., Campain, A. E., & Fraser‐Bell, S. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011599.pub2 · Cited by 68
The ocular renin–angiotensin system: A therapeutic target for the treatment of ocular disease
Giese, M. J., & Speth, R. C. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.11.002 · Cited by 74
A Multiethnic Study of Pre-Diabetes and Diabetes in LMIC
Shen, J., Kondal, D., Rubinstein, A., Irazola, V. E., Gutiérrez, L., Miranda, J. J., Bernabé‐Ortiz, A., Lazo-Porras, M., Levitt, N. S., Steyn, K., et al. (2016) · Global Heart · doi:10.1016/j.gheart.2015.12.015 · Cited by 76
A novel small molecule ameliorates ocular neovascularisation and synergises with anti-VEGF therapy
Sulaiman, R. S., Merrigan, S., Quigley, J., Qi, X., Lee, B., Boulton, M. E., Kennedy, B. N., Seo, S.-Y., & Corson, T. W. (2016) · Scientific Reports · doi:10.1038/srep25509 · Cited by 68
Dodo, Y., Suzuma, K., Ishihara, K., Yoshitake, S., Fujimoto, M., Yoshitake, T., Miwa, Y., & Murakami, T. (2017) · Scientific Reports · doi:10.1038/s41598-017-05663-9 · Cited by 68
Diabetic Retinopathy: Focus on Minority Populations
Barsegian, A., Kotlyar, B., Lee, J., Salifu, M., & McFarlane, S. I. (2017) · International Journal of Clinical Endocrinology and Metabolism · doi:10.17352/ijcem.000027 · Cited by 71
An insight on ophthalmic drug delivery systems: focus on polymeric biomaterials-based carriers
Shafiq, M., Rafique, M., Cui, Y., Pan, L., Do, C.-W., & Ho, E. A. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.08.041 · Cited by 67
Prevalence and associated factors of diabetic retinopathy in Beijing, China: a cross-sectional study
Cui, J., Ren, J., Chen, D., Zhong, X., Yuan, M., Xu, J., You, Q. S., & Yang, J. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-015473 · Cited by 67
Fenofibrate and Diabetic Retinopathy
Knickelbein, J. E., Abbott, A. B., & Chew, E. Y. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0786-7 · Cited by 72
Potential regulatory mechanisms of lncRNA in diabetes and its complications
Feng, S., Yang, J., Yao, C. H., Yang, S., Zhu, Z.-M., Wu, D., Ling, H., & Zhang, L. (2016) · Biochemistry and Cell Biology · doi:10.1139/bcb-2016-0110 · Cited by 71
Diabetic Retinopathy: Battling the Global Epidemic
Das, A. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-21031 · Cited by 68
Midena, E., Bini, S., Martini, F., Convento, E., Pilotto, E., Micera, A., Esposito, G., & Vujosevic, S. (2018) · Retina · doi:10.1097/iae.0000000000002356 · Cited by 73
Gunasekeran, D. V., & Wong, T. Y. (2020) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/01.apo.0000656984.56467.2c · Cited by 75
“This is partly due to staggering growth in the burden of diabetes mellitus (DM),(8) whereby DR is a common end organ manifestation of DM.(9) Similarly, AMD and glaucoma are other leading causes of VI, driven by aging populations.”
BackgroundSelf-citationVitamin D Protects against Oxidative Stress and Inflammation in Human Retinal Cells
Fernández‐Robredo, P., González‐Zamora, J., Recalde, S., Bilbao‐Malavé, V., Bezunartea, J., Hernández, M., & García‐Layana, A. (2020) · Antioxidants · doi:10.3390/antiox9090838 · Cited by 70
“Diabetic retinopathy (DR) is the main cause of blindness among adults of working age globally [1].”
BackgroundLong‐term outcomes of vitrectomy for proliferative diabetic retinopathy
Schreur, V., Brouwers, J., van Huet, R. A. C., Smeets, S., Phan, M., Hoyng, C. B., de Jong, E. K., & Klevering, B. J. (2020) · Acta Ophthalmologica · doi:10.1111/aos.14482 · Cited by 66
“Proliferative diabetic retinopathy (PDR) is a sight-threatening complication of diabetes mellitus (DM), affecting 7% of all 425 million people living with DM (Yau et al. 2012).”
BackgroundTime in range centered diabetes care
Dovč, K., & Battelino, T. (2021) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.30.1 · Cited by 70
Mounirou, B. A. M., Adam, N. D., Yakoura, A. H., Aminou, M. S. M., Liu, Y., & Tan, L. (2022) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_480_21 · Cited by 66
Gingerol, a Natural Antioxidant, Attenuates Hyperglycemia and Downstream Complications
Alharbi, K. S., Nadeem, M. S., Afzal, O., Alzarea, S. I., Altamimi, A. S. A., Almalki, W. H., Mubeen, B., Iftikhar, S., Shah, L., & Kazmi, I. A. (2022) · Metabolites · doi:10.3390/metabo12121274 · Cited by 76
Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis
Virgili, G., Curran, K., Lucenteforte, E., Pető, T., & Parravano, M. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007419.pub7 · Cited by 92
Shoaib, M. R., Emara, H. M., Zhao, J., El‐Shafai, W., Soliman, N. F., Mubarak, A. S., Omer, O. A., El‐Samie, F. E. A., & Esmaiel, H. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107834 · Cited by 66
Rodríguez‐Poncelas, A., Miravet-Jiménez, S., Casellas, A., Barrot, J., Franch‐Nadal, J., López‐Simarro, F., Mata‐Cases, M., & Mundet, X. (2015) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2015-306683 · Cited by 66
Banerjee, D., Leong, W. B., Arora, T., Nolen, M., Punamiya, V., Grunstein, R. R., & Taheri, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079521 · Cited by 68
“9 years) compared to the study by Yau et al [20].”
ResultInfluentialLammer, J., Bolz, M., Baumann, B., Pircher, M., Gerendas, B. S., Schlanitz, F. G., Hitzenberger, C. K. F., & Schmidt-Erfurth, U. M. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.13-13539 · Cited by 66
“5%), with a five-fold increased risk for subjects with type 1 diabetes (duration ‡ 20 years) compared to those with type 2 diabetes (duration < 10 years).(3,4) The Wisconsin Epidemiologic Study of Diabetic Retinopathy has reported a 10-year incidence of DME of approximately 20% in individuals with type 1 diabetes and…”
BackgroundAutomated Screening for Diabetic Retinopathy – A Systematic Review
Nørgaard, M. F., & Grauslund, J. (2018) · Ophthalmic Research · doi:10.1159/000486284 · Cited by 66
Self-citationCost Effectiveness of Treatments for Diabetic Retinopathy: A Systematic Literature Review
Maniadakis, N., & Konstantakopoulou, E. (2019) · PharmacoEconomics · doi:10.1007/s40273-019-00800-w · Cited by 69
Rosenblatt, A., Udaondo, P., Cunha-Vaz, J., Sivaprasad, S., Bandello, F. M., Lanzetta, P., Kodjikian, L., Goldstein, M., Habot‐Wilner, Z., Loewenstein, A., et al. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.10.005 · Cited by 67
Elevated plasma trimethylamine-N-oxide levels are associated with diabetic retinopathy
Liu, W., Wang, C., Xia, Y., Xia, W. T., Liu, G., Ren, C., Gu, Y., Li, X., & Lu, P. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01610-9 · Cited by 71
“6% among individuals with diabetes [2].”
Glycated hemoglobin A1C and vitamin D and their association with diabetic retinopathy severity
Long, M., Wang, C., & Liu, D. (2017) · Nutrition and Diabetes · doi:10.1038/nutd.2017.30 · Cited by 65
Ceravolo, I., Oliverio, G. W., Alibrandi, A., Bhatti, A., Trombetta, L., Ręjdak, R., Toro, M. D., & Trombetta, C. J. (2020) · Diagnostics · doi:10.3390/diagnostics10060413 · Cited by 69
“Diabetic retinopathy (DR) is the most frequent complication of diabetes and represents one of the leading causes of legal blindness, primarily as a result of diabetic macular edema (DME) [1,2].”
BackgroundIntraocular fluid biomarkers (liquid biopsy) in human diabetic retinopathy
Midena, E., Frizziero, L., Midena, G., & Pilotto, E. (2021) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-021-05285-y · Cited by 65
Hashemi, H., Rezvan, F., Pakzad, R., Ansaripour, A., Heydarian, S., Yekta, A., Ostadimoghaddam, H., Pakbin, M., & Khabazkhoob, M. (2019) · Seminars in Ophthalmology · doi:10.1080/08820538.2021.1962920 · Cited by 70
“Although some authors have attributed this difference to differences in the prevalence of diabetes between men and women,(124) the results of merging 90 studies showed no intergender difference in the prevalence of diabetes, which was consistent with the results of other meta-analyses.(2,8) Although the primary study…”
ResultInfluentialAnimal models of diabetic microvascular complications: Relevance to clinical features
Singh, R., Farooq, S. A., Mannan, A., Singh, T. G., Najda, A., Zawiślak, G., Albadrani, G. M., Sayed, A. A., & Abdel‐Daim, M. M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112305 · Cited by 67
Artificial intelligence in diabetic retinopathy: Bibliometric analysis
Poly, T. N., Islam, M. M., Walther, B. A., Lin, M. C., & Li, Y. (2023) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2023.107358 · Cited by 71
Jin, Y., & Arroo, R. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1020950 · Cited by 70
“4 million suffering from vision impairment (15, 16).”
BackgroundA Comprehensive Study of Retinal Vessel Classification Methods in Fundus Images
Amini, Z., Miri, M., Rabbani, H., & Kafieh, R. (2017) · Journal of Medical Signals & Sensors · doi:10.4103/2228-7477.205505 · Cited by 70
Circular RNAs: Novel Promising Biomarkers in Ocular Diseases
Guo, N., Liu, X., Pant, O. P., Zhou, D., Hao, J., & Lu, C. (2019) · International Journal of Medical Sciences · doi:10.7150/ijms.29750 · Cited by 65
“Diabetic retinopathy (DR) is the major microvascular complication of uncontrolled diabetes mellitus and also the leading cause of visual impairment and blindness worldwide [28].”
BackgroundDeliyanti, D., Alrashdi, S. F., Touyz, R. M., Kennedy, C., Jha, J. C., Cooper, M. E., Jandeleit-Dahm, K. A. M., & Wilkinson‐Berka, J. L. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.14100 · Cited by 69
“1091 Diabetic retinopathy (DR) is a leading cause of vision loss and blindness across the globe with ≈93 million people estimated to have DR and 29 million people vision-threatening DR.(1) The clinical hallmark of DR is damage to the retinal vasculature characterized by vascular permeability and edema due to breakdown…”
BackgroundInfluentialSong, S., Yu, X., Zhang, P., & Dai, H. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107641 · Cited by 65
Development and prospect of telemedicine
Su, Z., Li, C., Fu, H., Wang, L., Wu, M., & Feng, X. (2022) · Intelligent Medicine · doi:10.1016/j.imed.2022.10.004 · Cited by 80
A Review on Diabetic Retinopathy
Kour, V., Swain, J., Singh, J., Singh, H., & Kour, H. (2023) · Current Diabetes Reviews · doi:10.2174/0115733998253672231011161400 · Cited by 75
Optical coherence tomography in the management of diabetic macular oedema
Szeto, S., Lai, T. Y. Y., Vujosevic, S., Sun, J. K., Sadda, S. R., Tan, G. S. W., Sivaprasad, S., Wong, T. Y., & Cheung, C. Y.-L. (2023) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2023.101220 · Cited by 70
Self-citationInfluence of Glycosylated Hemoglobin on the Efficacy of Ranibizumab for Diabetic Macular Edema
Bansal, A. S., Khurana, R. N., Wieland, M. R., Wang, P.-W., Everen, S. A. V., & Tuomi, L. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.04.029 · Cited by 64
Patient Attitudes Toward Telemedicine for Diabetic Retinopathy
Valikodath, N. G., Leveque, T. K., Wang, S. Y., Lee, P. P., Newman-Casey, P. A., Hansen, S. O., & Woodward, M. A. (2016) · Telemedicine Journal and e-Health · doi:10.1089/tmj.2016.0108 · Cited by 65
A Novel Machine Learning Model Based on Exudate Localization to Detect Diabetic Macular Edema
Perdómo, O., Otálora, S., Rodríguez, F., Arévalo, J., & Gonzalez, F. A. (2016) · Ophthalmic Medical Image Analysis International Workshop (OMIA) · doi:10.17077/omia.1057 · Cited by 64
“…M. K. Garvin, J. Eye fundus image is a common clinical exams that presents some advantages as: high patient compliance, dilation not required in most cases, quick and simple technique, images can be saved and analyzed at a later time, and progression of diseases can be monitored over time[6,7,8,9].”
BackgroundTranslational Preclinical Pharmacologic Disease Models for Ophthalmic Drug Development
Shah, M., Cabrera-Ghayouri, S., Christie, L., Held, K. S., & Viswanath, V. (2019) · Pharmaceutical Research · doi:10.1007/s11095-019-2588-5 · Cited by 68
The SUSTech-SYSU dataset for automated exudate detection and diabetic retinopathy grading
Lin, L., Li, M., Huang, Y., Cheng, P., Xia, H., Wang, K., Yuan, J., & Tang, X. (2020) · Scientific Data · doi:10.1038/s41597-020-00755-0 · Cited by 74
“Diabetic retinopathy (DR) is one of the microvascular complications of diabetes mellitus and a leading cause of blindness among working-age adults in developed countries 1 .”
BackgroundImplementation of medical retina virtual clinics in a tertiary eye care referral centre
Kortuem, K., Fasler, K., Charnley, A., Khambati, H., Fasolo, S., Katz, M., Balaskas, K., Rajendram, R., HAMILTON, R. D., Keane, P. A., et al. (2018) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2017-311494 · Cited by 69
CTF-Net: Retinal Vessel Segmentation via Deep Coarse-To-Fine Supervision Network
Wang, K., Zhang, X., Huang, S., Wang, Q., & Chen, F. (2020) · IEEE International Symposium on Biomedical Imaging (ISBI) · doi:10.1109/isbi45749.2020.9098742 · Cited by 63
“Diabetic retinopathy (DR) is the leading cause of blindness among working aged adults around the world [1].”
BackgroundSelf-citationAcrolein: A Potential Mediator of Oxidative Damage in Diabetic Retinopathy
Alfarhan, M., Jafari, E. A., & Narayanan, S. P. (2020) · Biomolecules · doi:10.3390/biom10111579 · Cited by 69
“It is estimated that the prevalence of any form of DR is about 93 million worldwide [3].”
BackgroundA review of therapies for diabetic macular oedema and rationale for combination therapy
Amoaku, W. M. K., Saker, S., & Stewart, E. A. (2015) · Eye · doi:10.1038/eye.2015.110 · Cited by 71
Chisha, Y., Terefe, W., Assefa, H., & Lakew, S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171987 · Cited by 63
Toto, L., D’Aloisio, R., Nicola, M. D., Martino, G. D., Staso, S. D., Ciancaglini, M., Tognetto, D., & Mastropasqua, L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061181 · Cited by 63
“Diabetic retinopathy (DR) is one of the leading causes of vision loss and blindness in the working age population [1].”
BackgroundMei, X., Zhang, T., Ouyang, H., Lü, B., Wang, Z., & Ji, L. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.11.011 · Cited by 63
Huemer, J. C., Wagner, S. K., & Sim, D. A. (2020) · Clinical ophthalmology · doi:10.2147/opth.s261629 · Cited by 68
Teo, Z. L., Tham, Y.-C., Yu, M., Cheng, C.-Y., Wong, T. Y., & Sabanayagam, C. (2020) · Eye · doi:10.1038/s41433-020-0776-5 · Cited by 62
Self-citationTelemedicine for screening diabetic retinopathy: The NO BLIND Italian multicenter study
Sasso, F. C., Pafundi, P. C., Gelso, A., Bono, V., Costagliola, C., Marfella, R., Sardu, C., Rinaldi, L., Galiero, R., Acierno, C., et al. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3113 · Cited by 62
“The 15.5% of prevalence of DR in our subpopulation is in line with several data previously reported in the literature in our country and in Europe.2,30 This result shows, compared with the usual approach, that retinal photography is more cost‐effective.”
BackgroundResultInfluentialEmerging therapies in the management of macular edema: a review
Sacconi, R., Giuffrè, C., Corbelli, E., Borrelli, E., Querques, G., & Bandello, F. (2019) · F1000Research · doi:10.12688/f1000research.19198.1 · Cited by 62
Liu, K., Wang, H., He, W., Ye, J., Song, Y., Wang, Y., Liu, X., Wu, Z., Chen, S., Fan, K., et al. (2021) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-318690 · Cited by 70
Self-citationOcular findings among patients surviving COVID-19
Costa, Í. F., Bonifácio, L. P., Bellissimo‐Rodrigues, F., Rocha, E. M., Jorge, R., Bóllela, V. R., & Antunes-Foschini, R. (2021) · Scientific Reports · doi:10.1038/s41598-021-90482-2 · Cited by 62
Metabolomics in Diabetic Retinopathy: A Systematic Review
Hou, X.-W., Wang, Y., & Pan, C. (2021) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.62.10.4 · Cited by 70
Boehme, M. W. J., Buechele, G., Frankenhauser-Mannuss, J., Mueller, J., Lump, D., Boehm, B. O., & Rothenbacher, D. (2015) · BMC Public Health · doi:10.1186/s12889-015-2188-1 · Cited by 60
Body mass index and retinopathy in Asian populations with diabetes mellitus
Rooney, D. M., Lye, W. K., Tan, G. S. W., Lamoureux, E. L., Ikram, M. K., Cheng, C., Neelam, K., Zheng, Y. F., Mitchell, P. L. R., Wang, J. J., et al. (2014) · Acta Diabetologica · doi:10.1007/s00592-014-0602-2 · Cited by 67
“An estimated 93 million people have diabetic retinopathy (DR), the most common cause of blindness in working-age adults worldwide [1, 2].”
BackgroundSelf-citationRisk factors associated with diabetic macular edema
Diep, T. M., & Tsui, I. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.01.011 · Cited by 74
“8% of all people with diabetes, for an estimated 21 million cases worldwide [2,3].”
BackgroundCurrent and Next Generation Portable Screening Devices for Diabetic Retinopathy
Micheletti, J. M., Hendrick, A. M., Khan, F. N., Ziemer, D. C., & Pasquel, F. J. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816629158 · Cited by 64
“Based on individual-level data from population-based studies, the estimated prevalence of any retinopathy among patients with diabetes is around 35% (approximately 93 million people globally).(4) Once diagnosed, intensive glycemic and blood pressure control help reduce the risk of DR progression, however achieving rec…”
HbA1c, systolic blood pressure variability and diabetic retinopathy in Asian type 2 diabetics
Foo, V. H. X., Quah, J. H. M., Cheung, C. M. G., Tan, N. C., Zar, K. L. M., Chan, C. M., Lamoureux, E. L., Yin, W. T., Tan, G. S. W., & Sabanayagam, C. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12403 · Cited by 65
“Diabetes-related visual impairment places a significant burden on society,(3) with healthcare and economic burdens further compounded by the resulting decline in quality of life.(2) Well-established risk factors for DR include chronic hyperglycemia, or poor glycemic control (elevated HbA1c), and high systolic blood pr…”
BackgroundSelf-citationFukuda, T., Bouchi, R., Takeuchi, T., Nakano, Y., Murakami, M., Minami, I., Izumiyama, H., Hashimoto, K., Yoshimoto, T., & Ogawa, Y. (2017) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2017-000404 · Cited by 66
Jin, K., Pan, X., You, K., Wu, J., Liu, Z., Cao, J., Lou, L., Xu, Y., Su, Z., Yao, K., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-71622-6 · Cited by 59
Lee, S.-J., Kim, M., & Kim, Y. (2015) · Indian Journal of Ophthalmology · doi:10.4103/0301-4738.158069 · Cited by 68
Lu, Y., Serpas, L., Genter, P., Anderson, B., Campa, D., & Ipp, E. (2016) · Preventing Chronic Disease · doi:10.5888/pcd13.160193 · Cited by 60
Plasma level of miR-93 is associated with higher risk to develop type 2 diabetic retinopathy
Zou, H., Wang, Y., Gang, Q., Zhang, Y., & Sun, Y. (2017) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-017-3638-5 · Cited by 67
Liu, L., Zuo, Z., Si-jing, L., Liu, A., & Liu, X. (2017) · PubMed Central · doi:10.22038/ijbms.2017.9017 · Cited by 81
“DR remains the leading cause of blindness among working age people worldwide (5).”
BackgroundManagement of diabetic macular edema in Japan: a review and expert opinion
Terasaki, H., Ogura, Y., Kitano, S., Sakamoto, T., Murata, T., Hirakata, A., & Ishibashi, T. (2017) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-017-0537-6 · Cited by 63
“0% and in patients with a diabetes duration C 10 years relative to those with a duration \ 10 years [16].”
BackgroundFructus lycii: A Natural Dietary Supplement for Amelioration of Retinal Diseases
Neelam, K., Dey, S., Sim, R. Z. H., Lee, J., & Eong, K. A. (2021) · Nutrients · doi:10.3390/nu13010246 · Cited by 64
Cheng, C.-Y., Soh, Z. D., Majithia, S., Thakur, S., Rim, T. H., Tham, Y. C., & Wong, T. Y. (2020) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000304 · Cited by 64
“Other consortia include The Meta-Analysis for Eye Disease study group, and the International Eye Disease Consortium, who have reported on the global prevalence of diabetic retinopathy and retinal vein occlusion.(67,68) These consortia provide a crucial source of big data for regional disease surveillance and study of…”
BackgroundSelf-citationThe Pathogenesis and Therapeutic Approaches of Diabetic Neuropathy in the Retina
Oshitari, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22169050 · Cited by 60
“, proliferative diabetic retinopathy and/or diabetic macular edema [3].”
BackgroundSinger, M. A., Sheth, V. S., Mansour, S. E., Coughlin, B., & González, V. H. (2022) · Ophthalmology · doi:10.1016/j.ophtha.2022.01.015 · Cited by 60
Mason, R. H., Minaker, S. A., Luna, G. M. L., Bapat, P., Farahvash, A., Garg, A., Bhambra, N., & Muni, R. H. (2022) · Eye · doi:10.1038/s41433-022-02127-x · Cited by 65
Cahoon, J. M., Rai, R. R., Carroll, L. S., Uehara, H., Zhang, X., O’Neil, C. L., Medina, R. J., Das, S. K., Muddana, S. K., Olson, P. R., et al. (2015) · Diabetes · doi:10.2337/db14-1030 · Cited by 64
Self-citationChung, Y.-R., Choi, J. A., Koh, J., & Yoon, Y. H. (2017) · Journal of Diabetes Research · doi:10.1155/2017/1763292 · Cited by 60
“The World Health Organization has estimated that DR is responsible for 15–17% total blindness in the United States and Europe [2, 42, 43, 45].”
BackgroundA new chaotic model for glucose-insulin regulatory system
Shabestari, P. S., Panahi, S., Hatef, B., Jafari, S., & Sprott, J. C. (2018) · Chaos Solitons & Fractals · doi:10.1016/j.chaos.2018.04.029 · Cited by 62
Bardisi, W. M., Magliah, S. F., Attah, M. A., & Khorsheed, M. M. (2018) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_85_18 · Cited by 70
Cooper, O. A. E., Taylor, D. J., Crabb, D. P., Sim, D. A., & McBain, H. B. (2019) · Diabetic Medicine · doi:10.1111/dme.14125 · Cited by 65
Garg, I., Uwakwe, C., Le, R., Lu, E. S., Cui, Y., Wai, K. M., Katz, R., Zhu, Y., Moon, J. Y., Li, C. Y., et al. (2022) · Ophthalmology Science · doi:10.1016/j.xops.2022.100144 · Cited by 59
“Approximately one-third of them are estimated to have diabetic retinopathy (DR), and a further one-third of those develop vision-threatening DR, that is, proliferative DR (PDR) or diabetic macular edema (DME).(2) Considering its economic burden, efficient management depends on early”
BackgroundWidyaputri, F., Rogers, S. L., Kandasamy, R., Shub, A., Symons, R. C. A., & Lim, L. L. (2022) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2022.0050 · Cited by 49
Self-citationThrombosis and Hemorrhage in Diabetic Retinopathy: A Perspective from an Inflammatory Standpoint
Murugesan, N., Üstünkaya, T., & Feener, E. P. (2015) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0035-1556731 · Cited by 59
Boynton, G. E., Stem, M. S., Kwark, L., Jackson, G. R., Farsiu, S., & Gardner, T. W. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2014.12.001 · Cited by 59
“Exclusion criteria for the post-PRP group and treatment-naïve groups were: (1) any eye disease other than PDR; (2) history of drug or alcohol abuse; (3) neurologic or systemic disease that could impair vision; (4) hospitalization within 1 month prior to enrollment; (5) difference in two recent consecutive hemoglobin A…”
BackgroundMethodInfluentialChanges observed in diabetic retinopathy: eight-year follow-up of a Spanish population
Romero-Aroca, P., de la Riva-Fernandez, S., Valls-Mateu, A., Sagarra-Alamo, R., Moreno-Ribas, A., & Soler, N. (2016) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2015-307689 · Cited by 55
Screening Intervals for Diabetic Retinopathy and Implications for Care
Scanlon, P. H. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0928-6 · Cited by 59
Reversible retinal vessel closure from VEGF-induced leukocyte plugging
Liu, Y., Shen, J., Fortmann, S. D., Wang, J., Vestweber, D., & Campochiaro, P. A. (2017) · JCI Insight · doi:10.1172/jci.insight.95530 · Cited by 59
“Introduction Diabetic retinopathy is a major complication of diabetes that is a highly prevalent cause of moderate and severe vision loss (1).”
BackgroundSelf-citationKamran, S. A., Saha, S., Sabbir, A. S., & Tavakkoli, A. (2019) · International Conference on Machine Learning and Applications · doi:10.1109/icmla.2019.00165 · Cited by 71
“∂ξ ∂Xl = ∂ξ ∂τ(XStagel ) × Stage∏ j=1 [ ∂τ(Xjl ) ∂Xjl ] (5) Equation (5) represents the gradient calculated for the entire network chain distributed over stages of optimization.”
BackgroundShin, Y., Nam, K. Y., Lee, S. E., Lee, M., Lim, H., Jo, Y. J., & Kim, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-52354-8 · Cited by 59
Metadata
- Authors
- Yau, J. W. Y., Rogers, S. L., Kawasaki, R., Lamoureux, E. L., Kowalski, J. W., Bek, T., Chen, S.-J., Dekker, J. M., Fletcher, A., Grauslund, J., Haffner, S., Hamman, R. F., Ikram, M. K., Kayama, T., Klein, B. E. K., Klein, R., Krishnaiah, S., Mayurasakorn, K., O’Hare, J. P., Orchard, T. J., Porta, M., Rema, M., Roy, M. S., Sharma, T., Shaw, J., Taylor, H., Tielsch, J. M., Varma, R., Wang, J. J., Wang, N., West, S., Xu, L., Yasuda, M., Zhang, X., Mitchell, P., Wong, T. Y., & for the Meta-Analysis for Eye Disease (META-EYE) Study Group
- Affiliations
- The University of Melbourne (AU)
- Allergan (United States) (US)
- Aarhus University Hospital (DK)
- Taipei Veterans General Hospital (TW)
- Amsterdam Public Health (NL)
- London School of Hygiene & Tropical Medicine (GB)
- Odense University Hospital (DK)
- Shavano Park, Texas
- Colorado School of Public Health (US)
- Erasmus MC (NL)
- Yamagata University (JP)
- University of Wisconsin–Madison (US)
- L V Prasad Eye Institute (IN)
- Samut Sakhon Hospital (TH)
- University of Warwick (GB)
- University of Pittsburgh (US)
- University of Turin (IT)
- Madras Diabetes Research Foundation (IN)
- Rutgers New Jersey Medical School (US)
- Sankara Nethralaya (IN)
- Baker Heart and Diabetes Institute (AU)
- Johns Hopkins University (US)
- University of Southern California (US)
- The University of Sydney (AU)
- Beijing Tongren Hospital (CN)
- Johns Hopkins Hospital (US)
- Kyushu University (JP)
- Centers for Disease Control and Prevention (US)
- Corresponding author
- Wong, Tien Y.
- ORCID
- Rogers, Sophie L.
- Kawasaki, Ryo
- Lamoureux, Ecosse L.
- Bek, Toke
- Chen, Shih-Jen
- Fletcher, Astrid
- Grauslund, Jakob
- Hamman, Richard F.
- Ikram, M. Kamran
- Klein, Barbara E.K.
- Klein, Ronald
- Krishnaiah, Sannapaneni
- Mayurasakorn, Korapat
- Orchard, Trevor J.
- Porta, Massimo
- Sharma, Tarun
- Shaw, Jonathan
- Taylor, Hugh
- Tielsch, James M.
- Varma, Rohit
- Wang, Jie Jin
- West, Sheila
- Xu, Liang
- Zhang, Xinzhi
- Mitchell, Paul
- Wong, Tien Y.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-02-10
- Volume
- 35
- Issue
- 3
- Pages
- 556-564
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3322721
- OpenAlex
- W2138480916
- Cited by
- 4,985
- References
- 38
- Citations by year
- 2026: 374 · 2025: 447 · 2024: 477 · 2023: 429 · 2022: 499 · 2021: 544 · 2020: 520 · 2019: 365 · 2018: 331 · 2017: 305 · 2016: 238 · 2015: 198 · 2014: 139 · 2013: 80 · 2012: 30
- FWCI
- 21.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, cc-by-nc-nd)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
- National University of Singapore (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Research to Prevent Blindness
- Hyderabad Eye Research Foundation
- Oogfonds
- Algemene Nederlandse Vereniging ter voorkoming van Blindheid
- National Institutes of Health
- Allergan
- Medical Research Council
- National Eye Institute (EY0-6594, R01 EY 09860, R01EY009860, U10EY006594, R01EY016379)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- diabetic retinopathy, vision-threatening diabetic retinopathy, proliferative diabetic retinopathy, diabetic macular edema, global prevalence, risk factors, diabetes duration, glycemic control, HbA1c, blood pressure, type 1 diabetes, type 2 diabetes, fundus images, public health burden
- MeSH terms
- Adult, Aged, Blood Glucose, Blood Pressure, Diabetic Retinopathy, Female, Humans, Male, Middle Aged, Risk Factors, Prevalence, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.